Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists develop novel bovine TB vaccine
The vaccine is the first to be compatible with a synthetic version of the tuberculin skin test.

Vaccine compatible with synthetic PPD skin test 

Researchers at the University of Surrey have produced a novel vaccine and complementary skin test to protect cattle against bovine Tb (bTB).

The vaccine, reported in the journal Scientific Reports, is the first to be compatible with a synthetic version of the tuberculin skin test (PPD), a test that is legally required in the UK for the surveillance of TB in cattle.

Researchers say the discovery could allow farmers and veterinary surgeons to protect their animals with the new BCG vaccine, while still maintaining a diagnostic test that will detect TB.

“In order to control the spread of bovine TB, effective vaccination and accurate early diagnosis of the disease are critical,” said Johnjoe McFadden, Professor of Molecular Genetics at the University of Surrey.
“This new vaccine provides protection against bovine TB and will help in the fight against this deadly disease which infects over 50 million cattle worldwide and is economically devastating to farmers.”

The BCG vaccine is currently used to protect humans and is effective in cattle. However, it is incompatible with the PPD skin test.
Cattle that receive the BCG vaccine - which contains a harmless strain of Mycobacterium bovis - produce a positive PPD test that makes it impossible to tell if the animal has TB or has been vaccinated against the disease.

It is for this reason that the BCG vaccine is banned in most countries, meaning vets continue to use the PPD skin test to diagnose the disease in cattle.

In this latest study, researchers set out to create a new strain of the BCG vaccine that lacks some of the proteins shared with Mycobacterium bovis. They did this by injecting cows with BCG strains that had each lost a single gene and measured the survival rates.

By employing this method, the researchers were able to identify genes that could be removed from BCG, without compromising its ability to work as a live vaccine.

The team deleted the dispensable genes from the BCG chromosome to make a BCG-minus strain. The deleted proteins were then used to develop a new synthetic skin test that would be positive for animals exposed to TB, but negative for animals vaccinated against the BCG-minus strain.

Subsequent tests of the synthetic PPD test on guinea pigs revealed that those infected with TB tested positive for the disease. Guinea pigs vaccinated with the BCG-minus vaccine, however, did not.

“The next stage of our work will be to demonstrate that both synthetic skin test and BCG-minus vaccine works in cattle herds,” professor McFadden continued. “If they do, then it will be possible to vaccinate cattle against TB yet retain the value of skin test for diagnosis.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.